3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Myeloproliferative Disorders
2
Anemia
2
Primary Myelofibrosis
1
Myelodysplastic Syndromes
1
Interventions
ruxolitinib
9
navitoclax
4
Tacrolimus
4
Cyclophosphamide
4
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
venetoclax
2
fludarabine phosphate
2
fludarabine
2
Melphalan
2
Busulfan
2
veliparib
1
selinexor
1
pevonedistat
1
luspatercept
1
letermovir
1
itacitinib
1
imetelstat
1
givinostat hydrochloride
1
givinostat
1
fedratinib
1
elotuzumab
1
canakinumab
1
avelumab
1
Valganciclovir
1
Topotecan
1
Therapeutics
1
Stem Cell Transplantation
1
Sirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Primary Myelofibrosis
×
luspatercept
×
Clear all
NCT04717414
2025-07-10
INDEPENDENCE
Celgene
Phase 3
Active not recruiting
313 enrolled